Free Trial
NASDAQ:VIRI

Virios Therapeutics 8/10/2023 Earnings Report

Virios Therapeutics logo
$5.48 +0.07 (+1.29%)
As of 04/30/2025

Virios Therapeutics EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Virios Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Virios Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Virios Therapeutics' next earnings date is estimated for Wednesday, May 7, 2025, based on past reporting schedules.

Conference Call Resources

Virios Therapeutics Earnings Headlines

Dogwood Therapeutics Inc (DWTX)
Dogwood prices 578,950 shares at $8.26 in registered direct offering
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that Elon Musk himself believes "will be the biggest product ever of any kind". One well-connected Silicon Valley insider has uncovered a way for anybody to claim a stake in Optimus with as little as $100. All you'll need is a regular brokerage account.
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
See More Virios Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Virios Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Virios Therapeutics and other key companies, straight to your email.

About Virios Therapeutics

Virios Therapeutics (NASDAQ:VIRI), a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

View Virios Therapeutics Profile

More Earnings Resources from MarketBeat